What monitoring is required for a dog on long-term meloxicam therapy and how do I minimize renal and GI risk?

Question

Accepted Answer

Long-term meloxicam monitoring in dogs centers on periodic renal and hepatic biochemistry, with risk minimization built around hydration status, drug interactions, and gastrointestinal protection. Baseline bloodwork before initiating therapy and periodic rechecks during long-term use are the standard of care. The monitoring interval should be individualized, with more frequent assessment in patients with pre-existing renal, hepatic, or cardiovascular disease. Dogs at greatest risk for renal toxicity are those that are dehydrated, on concurrent diuretic therapy, or those with existing renal, cardiovascular, or hepatic dysfunction. 135 Renal parameters to track include blood urea nitrogen (BUN), creatinine, and urinalysis. In the 3-day injectable safety study, BUN increases occurred at the 1× recommended dose, and two dogs developed acute renal failure at 5× the recommended dose, with renal histopathology showing dilated tubules, interstitial inflammation, and papillary tip necrosis at doses as low as 1×. 3 In post-approval surveillance, azotemia, elevated creatinine, and renal failure have all been reported at clinical doses. 5 In cases of impaired renal function, dose reduction is recommended. 6 Hepatic monitoring should include alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Elevated liver enzymes have been reported in post-approval adverse event surveillance. 5 In the injectable safety study, ALP was significantly increased at 1× and 5× doses. 3 Hepatotoxicity is considered rare and largely idiosyncratic. 2 Gastrointestinal signs — vomiting, soft stools, diarrhea, and inappetence — are the most commonly reported adverse reactions in clinical use. In the 224-dog field study, gastrointestinal abnormalities were the leading adverse event category. 5 Post-approval reporting has documented vomiting, diarrhea, melena, and gastrointestinal ulceration. 5 In the 6-month oral safety study, gastrointestinal distress occurred across all dose groups including co